Rocket Pharmaceuticals Receives FDA Fast Track And Orphan Drug Designations For RP-A601 Gene Therapy For PKP2 Arrhythmogenic Cardiomyopathy
Portfolio Pulse from Benzinga Newsdesk
Rocket Pharmaceuticals has received FDA Fast Track and Orphan Drug Designations for its RP-A601 gene therapy for PKP2 Arrhythmogenic Cardiomyopathy. This will expedite the development and review process for the therapy.
June 08, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Rocket Pharmaceuticals' stock may see a positive impact as the company receives FDA Fast Track and Orphan Drug Designations for its RP-A601 gene therapy.
The FDA Fast Track and Orphan Drug Designations will expedite the development and review process for Rocket Pharmaceuticals' RP-A601 gene therapy. This is likely to be seen as a positive development by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100